ATE519773T1 - Nanopartikel aus gemcitabinderivaten - Google Patents

Nanopartikel aus gemcitabinderivaten

Info

Publication number
ATE519773T1
ATE519773T1 AT05857322T AT05857322T ATE519773T1 AT E519773 T1 ATE519773 T1 AT E519773T1 AT 05857322 T AT05857322 T AT 05857322T AT 05857322 T AT05857322 T AT 05857322T AT E519773 T1 ATE519773 T1 AT E519773T1
Authority
AT
Austria
Prior art keywords
derivatives
nanoparticles
gemcita
binder
difluoro
Prior art date
Application number
AT05857322T
Other languages
English (en)
Inventor
Veronique Rosilio
Jack-Michel Renoir
Patrick Couvreur
Flavio Rocco
Luigi Cattel
Barbara Stella
Original Assignee
Centre Nat Rech Scient
Univ Paris Sud 11
Flavio Rocco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Paris Sud 11, Flavio Rocco filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE519773T1 publication Critical patent/ATE519773T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05857322T 2004-06-30 2005-06-23 Nanopartikel aus gemcitabinderivaten ATE519773T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0451365A FR2874016B1 (fr) 2004-06-30 2004-06-30 Nanoparticules de derives de la gemcitabine
PCT/FR2005/050488 WO2006090029A1 (fr) 2004-06-30 2005-06-23 Nanoparticules de derives de la gemcitabine

Publications (1)

Publication Number Publication Date
ATE519773T1 true ATE519773T1 (de) 2011-08-15

Family

ID=34945701

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05857322T ATE519773T1 (de) 2004-06-30 2005-06-23 Nanopartikel aus gemcitabinderivaten
AT09152764T ATE520703T1 (de) 2004-06-30 2005-06-23 Einsatz von squalenhaltiger säure für die formulierung eines aktiven prinzips im nanoteilchenzustand

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT09152764T ATE520703T1 (de) 2004-06-30 2005-06-23 Einsatz von squalenhaltiger säure für die formulierung eines aktiven prinzips im nanoteilchenzustand

Country Status (11)

Country Link
US (2) US7704972B2 (de)
EP (3) EP2055711B1 (de)
JP (2) JP4927726B2 (de)
CN (2) CN102335436B (de)
AT (2) ATE519773T1 (de)
CA (2) CA2572380C (de)
DK (2) DK1761551T3 (de)
ES (2) ES2371411T3 (de)
FR (1) FR2874016B1 (de)
PT (2) PT2055711E (de)
WO (1) WO2006090029A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776100T3 (es) * 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
FR2931152B1 (fr) * 2008-05-16 2010-07-30 Centre Nat Rech Scient Nouveau systeme de transfert d'acide nucleique
WO2010039039A1 (en) * 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
FR2937537A1 (fr) * 2008-10-29 2010-04-30 Centre Nat Rech Scient Nanoparticules de statine
FR2937549B1 (fr) * 2008-10-29 2011-04-01 Centre Nat Rech Scient Nanoparticules de derives beta-lactamine
US9517476B2 (en) * 2008-10-31 2016-12-13 Hitachi Koki Co., Ltd. Centrifuge with acceleration and deceleration time display
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
FR2988092B1 (fr) 2012-03-16 2014-04-25 Centre Nat Rech Scient Complexes de vitamine c, nanoparticules desdits complexes, procedes pour leur preparation, leurs compositions, leurs utilisations cosmetiques et procede de traitement cosmetique
CN104968353B (zh) 2012-11-13 2017-12-22 博研医药开发股份有限公司 吉西他滨前药及其用途
EP2742955A1 (de) 2012-12-12 2014-06-18 Centre National De La Recherche Scientifique Nanopartikel auf Grundlage eines Biokonjugats von GAG
CN105636583B (zh) * 2013-09-13 2019-08-20 板井昭子 水溶液制剂及其制造方法
US10517822B2 (en) 2013-11-06 2019-12-31 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
CN103599073A (zh) * 2013-11-15 2014-02-26 无锡中科光远生物材料有限公司 一种负载有靶向抗癌药物的plga微米颗粒的制备方法
JP6212831B2 (ja) * 2013-12-04 2017-10-18 杭州源昶医薬科技有限公司 ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
CN105030682B (zh) * 2015-06-24 2018-02-09 广州复大医疗股份有限公司 一种纳米微粒胶体及其制备方法与用途
EP3439666A4 (de) 2016-05-20 2019-12-11 The University of Chicago Nanopartikel zur chemotherapie, gezielte therapie, photodynamische therapie, immuntherapie und alle kombinationen davon
TWI719182B (zh) * 2017-03-29 2021-02-21 國立交通大學 奈米組成物、其製造方法及其用途
US11306111B2 (en) 2017-07-31 2022-04-19 January Therapeutics, Inc. Organophosphate derivatives
EP3638367A4 (de) 2017-08-02 2021-07-21 The University of Chicago Nanoskalige metallorganische schichten und metallorganische nanoplatten für die röntgenstrahlinduzierte photodynamische therapie, strahlentherapie, dynamische strahlentherapie, chemotherapie, immuntherapie und eine beliebige kombination davon
WO2019169323A1 (en) * 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions
WO2019204869A1 (en) 2018-04-26 2019-10-31 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs
EP3628735A1 (de) 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense-rna-targeting pmp22 zur behandlung der charcot-marie-tooth-1a-erkrankung
WO2020247912A1 (en) * 2019-06-06 2020-12-10 Board Of Regents, The University Of Texas System Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
FR3110427B1 (fr) 2020-05-20 2023-07-14 Laboratoires Eriger Conjugué terpenique de couplage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
ATE236188T1 (de) 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
FR2808691B1 (fr) * 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine

Also Published As

Publication number Publication date
ATE520703T1 (de) 2011-09-15
EP1925624A1 (de) 2008-05-28
US7704972B2 (en) 2010-04-27
CN102335436A (zh) 2012-02-01
ES2372141T3 (es) 2012-01-16
CN101061131A (zh) 2007-10-24
JP5552473B2 (ja) 2014-07-16
EP1761551A1 (de) 2007-03-14
CA2805761A1 (fr) 2006-08-31
ES2371411T3 (es) 2012-01-02
US8044034B2 (en) 2011-10-25
FR2874016B1 (fr) 2006-11-24
CN101061131B (zh) 2011-10-05
JP2008504353A (ja) 2008-02-14
CN102335436B (zh) 2014-10-08
JP4927726B2 (ja) 2012-05-09
US20100160249A1 (en) 2010-06-24
WO2006090029A1 (fr) 2006-08-31
JP2012102107A (ja) 2012-05-31
CA2572380A1 (fr) 2006-08-31
CA2572380C (fr) 2013-11-19
DK1761551T3 (da) 2011-11-28
PT2055711E (pt) 2011-12-07
EP2055711A1 (de) 2009-05-06
PT1761551E (pt) 2011-11-24
EP2055711B1 (de) 2011-08-17
US20090130214A1 (en) 2009-05-21
CA2805761C (fr) 2016-10-04
DK2055711T3 (da) 2011-12-12
EP1761551B1 (de) 2011-08-10
FR2874016A1 (fr) 2006-02-10

Similar Documents

Publication Publication Date Title
ATE519773T1 (de) Nanopartikel aus gemcitabinderivaten
CR7718A (es) Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso
WO2010048552A3 (en) Methods of using oligomeric compounds comprising 2'-substituted nucleosides
EP2266569A3 (de) Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
CY1113063T1 (el) Παραγωγα πουρινης για χρηση ως αγωνιστες των α2α υποδοχεων αδενοσινης
NO20071853L (no) Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose.
WO2008131860A3 (de) Pyridoncarboxamide, diese enthaltende nutzpflanzenschützende mittel und verfahren zu ihrer herstellung und deren verwendung
BRPI0307117B8 (pt) amidas de ácido antranílico e seus derivados, bem como seus usos como compostos ativos cosméticos e farmacêuticos
CY1112831T1 (el) Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
BRPI0515478A (pt) derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
ATE551988T1 (de) Orale zusammensetzungen, ihre herstellung und verwendung
WO2008046758A3 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
CR9703A (es) Derivados de pirazolona
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
DE602005014341D1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
ES2054949T3 (es) Precursores de dopamina.
GEP201606545B (en) 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections
Moore et al. Ultraviolet irradiation of pyrimidine derivatives
DK1161228T3 (da) Præparat omfattende isoquercetin og ascorbinsyre i en sustained release-form
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DK1377164T3 (da) Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo
DE50308003D1 (de) St rkederivate, st rke-wirkstoff-konj ugate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TW200602315A (en) Substituted pyrazinecarboxanilide derivatives or salts thereof, intermediates thereof, agrohorticultural agents, and method for use the same
CN103130769B (zh) 一种3-二氟乙氧基-吡唑酰胺类化合物及其应用

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1761551

Country of ref document: EP